Human antibodies targeting TROP2 inhibited tumor cell proliferation and migration, induced apoptosis, and suppressed breast cancer xenograft growth in a dose-dependent manner (Lin et al., 2014). The gene discussed is TACSTD2; the disease is neoplasm.